Serina Therapeutics, Inc. (SER)

Every figure this model derived for SER, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 66,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 23,024,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 25,030,000 AssetsCurrent 2026-06-30
current liabilities 3,762,000 LiabilitiesCurrent 2026-06-30
equity 18,730,000 StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest 2026-06-30
interest expense 596,000 InterestExpenseNonoperating 2026-06-30
ocf -21,135,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 130,000 RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31
sbc 4,075,000 AllocatedShareBasedCompensationExpense 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up SER on one particular measure came for.

RatioValue
current ratio6.65
current ratio reported6.65
deferred revenue growth-2.83
dilution pct38.5
growth cv2.03
interest cover-40.31
revenue growth132.14
revenue growth per share67.61
rule of 40-18346.32

What to be careful about

What this model itself distrusts about SER's figures. Written by the derivation as it ran, not added afterwards.